Edwards Lifesciences Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 4:30PM CDT
Zacks Investment Research upgraded Edwards Lifesciences to a Zacks Rank #2 (Buy).
Myriad Genetics Is Saving Lives With New Products
at Investor's Business Daily - Thu Apr 17, 2:50PM CDT
Specialties are in vogue at many companies these days, but there's always room for diversifying products, generating revenue streams and expanding the clientele. Proving that point is Myriad Genetics, a molecular diagnostic company based in Salt Lake...
ImmunoGen, Inc. (IMGN) in Focus: Stock Rallies 11% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 17, 7:44AM CDT
ImmunoGen, Inc. was a big mover last session, as the company saw its shares surge 11% on the day.
Kythera Biopharmaceuticals, Inc. (KYTH) in Focus: Stock Surges 9.9 % - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:44AM CDT
Kythera Biopharmaceuticals, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.
Amicus Therapeutics (FOLD) Crumbles: Stock Falls by 8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 16, 7:33AM CDT
Amicus has not seen any positive earnings estimate revisions for the current quarter along with a significant decline in its share price for the past month
The Global Market for Biomarkers: Concise Analysis of the $25 Billion Industry
M2 - Tue Apr 15, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/r7r264/the_global_market) has announced the addition of the "The Global Market for Biomarkers: Cancer Markers, Cardiac Markers, Blood Markers, Endocrine Markers, Infectious Disease and Neurological Disease Markers" report to their offering. The global medical biomarker market is valued at about $25.9 billion for 2013, an increase of 10.2% since last year. Many biomarkers are now successfully marketed with several of them part of a routine diagnostic and treatment plan, with new products in the pipeline. Biomarkers are anatomic, physiologic, genetic, biochemical or molecular parameters. Biomarkers are detectable and measureable by a variety of methods including laboratory assays and medical imaging. Each biomarker is characteristic as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention. An example is creatine kinase, or CK-MB, a marker that facilitates high-energy phosphates in the body's tissues, and can suggest a cardiovascular event when levels are high. The cancer biomarker, or tumor marker, market is one of the more advanced segments with viable products, and currently the largest segment, according to the report. The report says the majority of competitive participation for medical biomarkers is in the United States and Europe. However, competition is steadily escalating in the United States and Europe, which is encouraging more participation in other areas such as Asia and Latin America. There are numerous companies in the market, including multiproduct companies such as Abbott and Roche, as well as small niche developers, such as 20/20 GeneSystems, CardioDx or MemoryDx. Key Topics Covered: Chapter One: Executive Summary Chapter Two: Introduction To The Medical Biomarkers Industry Chapter Three: Industry Trends Chapter Four: Biomarkers In Cancer Chapter Five: Biomarkers In Cardiovascular Disease And Blood Disorders Chapter Six: Biomarkers In Endocrine And Immune Disorders Chapter Seven: Biomarkers In Infectious Disease Chapter Eight: Biomarkers In Nervous System Disorders Chapter Nine: Market Summary Chapter Ten: Company Profiles - 20/20 GeneSystems - Abbott Laboratories - Affymetrix - Agendia - Alere - Beckman Coulter - Becton Dickinson - Biocartis SA - Biodesix - bioMerieux - BioReference Laboratory - bioTheranostics - CardioDX - Celera Alameda - Clarient - deCODE Genetics - DiaGenic - Genomic Health - Johnson & Johnson - Life Techologies - Memory Dx - Myriad Genetics - Nanostring Technologies - OPKO Health - Provista Dx - Qiagen - Roche - Seimens Healthcare - Tethys Bioscience - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/r7...bal_market
Ambit Biosciences Slumps: AMBI Falls 13.0% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 15, 7:40AM CDT
Ambit Biosciences falls 13% last trading session, continuing the downtrend
Quest Diagnostics Raised to Buy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 4:32PM CDT
Adjusted earnings per share of Quest Diagnostic came in at $1.03, beating the Zacks Consensus Estimate of 94 cents by 9.6%, and exceeding the company's prior-year earnings by 2%.
Laboratory Service Providers Should Profit From This New Revenue Source
Bob Chandler, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Medical testing leaders such as Laboratory Corporation of America and Quest Diagnostics have disappointed investors with little to no sales and profit growth over the past couple years. Sluggish demand and collapsing prices have smothered...
Can Honeywell (HON) Surprise This Earnings Season? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 14, 9:20AM CDT
Honeywell is set to report first-quarter financial results before the market opens on Apr 17, 2014.
Qiagen Expands Personalized Healthcare Pipeline - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 2:20PM CDT
Qiagen acquires an exclusive worldwide license for the calreticulin (CALR) biomarker from CeMM Vienna.
Gilead Sciences (GILD) Falls: Stock Goes Down 7.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 8:00AM CDT
Gilead Sciences saw a big move last session, as the company’s shares fell by over 7% on the day.
Baxano Surgical, Inc. (BAXS) in Focus: Stock up 10.7% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 11, 7:44AM CDT
Baxano Surgical, Inc. was a big mover last session, as the company saw its shares rise nearly 11% on the day.
Investors are betting against Myriad (MYGN), Should You? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 8:02AM CDT
Investors are betting against Myriad (MYGN), Should You?
Enzymotec Ltd. (ENZY) in Focus: Stock Rallies 11.06% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:44AM CDT
Enzymotec Ltd. was a big mover last session, as the company saw its shares rise a little over 11% on the day.
Myriad Genetics Falls 1.34% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Apr 09, 4:35PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $38.83 to a high of $40.75. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $39.54 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
SmarTrend Watching for Potential Rebound in Shares of Myriad Genetics After 1.34% Loss
Comtex SmarTrend(R) - Wed Apr 09, 4:34PM CDT
Myriad Genetics (NASDAQ:MYGN) traded in a range yesterday that spanned from a low of $38.83 to a high of $40.75. Yesterday, the shares fell 1.3%, which took the trading range below the 3-day low of $39.54 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
The Nasdaq's 3 Most Hated Stocks
Sean Williams, The Motley Fool - Motley Fool - Wed Apr 09, 4:16PM CDT
Since hitting highs not seen in practically 14 years, the technology- and biotechnology-heavy Nasdaq Composite has been throttled, falling more than 5% on a trailing basis from the high point reached in early March. Comparatively speaking,...
Why Myriad Genetics (MYGN) is Poised to Beat Earnings Estimates Again - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:50AM CDT
Myriad Genetics (MYGN) has seen a nice short-term history of beating earnings estimates, and looks poised to crush analyst expectations in its next earnings report as well.
RadNet, Inc. (RDNT) in Focus: Stock Surges 9.8% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 09, 7:44AM CDT
RadNet, Inc. was a big mover last session, as the company saw its shares rise nearly 10% on the day.